BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34332092)

  • 1. Drugging the 'undruggable'. Therapeutic targeting of protein-DNA interactions with the use of computer-aided drug discovery methods.
    Radaeva M; Ton AT; Hsing M; Ban F; Cherkasov A
    Drug Discov Today; 2021 Nov; 26(11):2660-2679. PubMed ID: 34332092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging the 'undruggable' cancer targets.
    Dang CV; Reddy EP; Shokat KM; Soucek L
    Nat Rev Cancer; 2017 Aug; 17(8):502-508. PubMed ID: 28643779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies and progress for targeting the "undruggable" transcription factors.
    Zhuang JJ; Liu Q; Wu DL; Tie L
    Acta Pharmacol Sin; 2022 Oct; 43(10):2474-2481. PubMed ID: 35132191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas.
    Agrawal V; Su M; Huang Y; Hsing M; Cherkasov A; Zhou Y
    Molecules; 2019 Sep; 24(19):. PubMed ID: 31554191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in targeting 'undruggable' transcription factors with small molecules.
    Henley MJ; Koehler AN
    Nat Rev Drug Discov; 2021 Sep; 20(9):669-688. PubMed ID: 34006959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional and Novel Computer-Aided Drug Design (CADD) Approaches in the Anticancer Drug Discovery Process.
    Del Carmen Quintal Bojórquez N; Campos MRS
    Curr Cancer Drug Targets; 2023; 23(5):333-345. PubMed ID: 35792126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT proteins as novel targets for cancer drug discovery.
    Turkson J
    Expert Opin Ther Targets; 2004 Oct; 8(5):409-22. PubMed ID: 15469392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerases as anticancer targets.
    Delgado JL; Hsieh CM; Chan NL; Hiasa H
    Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting post-translational modification of transcription factors as cancer therapy.
    Qian M; Yan F; Yuan T; Yang B; He Q; Zhu H
    Drug Discov Today; 2020 Aug; 25(8):1502-1512. PubMed ID: 32540433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA binding proteins for cancer therapy.
    Shiroma Y; Takahashi RU; Yamamoto Y; Tahara H
    Cancer Sci; 2020 Apr; 111(4):1058-1064. PubMed ID: 32073717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
    Huang W; Dong Z; Chen Y; Wang F; Wang CJ; Peng H; He Y; Hangoc G; Pollok K; Sandusky G; Fu XY; Broxmeyer HE; Zhang ZY; Liu JY; Zhang JT
    Oncogene; 2016 Feb; 35(6):783-92. PubMed ID: 26073084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting transcription factors by small compounds--Current strategies and future implications.
    Hagenbuchner J; Ausserlechner MJ
    Biochem Pharmacol; 2016 May; 107():1-13. PubMed ID: 26686579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
    Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
    Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking Aim at the Undruggable.
    Coleman N; Rodon J
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-8. PubMed ID: 33989024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugging the undruggable: transcription therapy for cancer.
    Yan C; Higgins PJ
    Biochim Biophys Acta; 2013 Jan; 1835(1):76-85. PubMed ID: 23147197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Protein Degradation: An Important Tool for Drug Discovery for "Undruggable" Tumor Transcription Factors.
    Dai M; Radhakrishnan S; Li R; Tan R; Yan K; Fan G; Liu M
    Technol Cancer Res Treat; 2022; 21():15330338221095950. PubMed ID: 35466792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based drug discovery supports drugging 'undruggable' protein-protein interactions.
    Wang ZZ; Shi XX; Huang GY; Hao GF; Yang GF
    Trends Biochem Sci; 2023 Jun; 48(6):539-552. PubMed ID: 36841635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in cancer drug discovery targeting RAS.
    Wilson CY; Tolias P
    Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance.
    Rudolph J; Settleman J; Malek S
    Cancer Discov; 2021 Apr; 11(4):815-821. PubMed ID: 33811118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on the current status on virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part II.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(6):1337-1358. PubMed ID: 28039691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.